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over a 3-year time horizon, with a special focus on prophylaxis and treatment of 
invasive fungal infections (IFI). METHODS: This was a retrospective, single-center 
study on AML patients hospitalized for chemotherapy, neutropenia, and infections 
after myelosuppressive chemotherapy from January 2004 to December 2006. Data on 
occurrence of IFI, treatment patterns, and resource utilization were collected by chart 
review. Direct medical costs were calculated from hospital provider perspective. 
RESULTS: In total, 471 hospitalization episodes in 212 patients were eligible for 
analysis. Occurrence of IFI decreased from 5.9% in 2004 to 1.9% in 2006. Mean 
hospital stay decreased from 28.7 ± 17.9 days (2004) to 22.4 ± 11.8 days (2006) (P 
< 0.05). From 2004 to 2006, use of a single antifungal drug increased from 30.4% 
to 46.9% of episodes, whereas use of multiple antifungal drugs decreased from 24.4% 
to 13.1%. Single antifungal drug use was dominated by azoles and increased from 
23.7% (2004) to 43.4% of episodes (2006). Posaconzole monotherapy was applied 
in 26.7% of episodes. Use of liposomal amphotericin B declined from 21.4% to 3.8%, 
caspofungin from 19.3% to 8.1%, ﬂ uconazole from 25.2% to 11.9%, and voricon-
azole from 31.9% to 15.0%. Total costs per episode declined from c19,051 ± 19,024 
(2004) to c13,531 ± 9,260 (2006) (P < 0.05); main reduction was observed for anti-
mycotics, blood products, and hospital stay. CONCLUSIONS: These real-life data 
from a university hospital in Germany indicate that the antifungal management of 
AML patient hospitalized for chemotherapy, neutropenia, and infections after chemo-
therapy changed between 2004/5 and 2006. This change was accompanied by a 
decline in treatment costs. Results suggest that the introduction of posaconazole 
prophylaxis in 2006 has not only reduced the use of antifungal therapies but also the 
need for treatment with multiple antifungal drugs.
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Prostate cancer is the most common form of cancer in UK men and incidence is on 
the rise, primarily driven by increased screening. Low-risk prostate cancer has disease-
speciﬁ c survival consistently over 95%. Consequently, the UK has deemed radical 
treatments (RTs) comprising radical prostatectomy, radiotherapy, and brachytherapy 
as unnecessary for low-risk prostate cancer and recommends active surveillance (AS). 
AS does not address the disutility for patients living with cancer and in real-life over 
50% of patients proceed to RT. Alternative “focal therapies” for this patient popula-
tion are therefore generating interest. OBJECTIVES: Determine the cost-effectiveness 
of AS in the UK as practiced and contrast with focal therapy. METHODS: A Markov 
model was used to evaluate the cost-utility of treatments for low-risk prostate cancer. 
Input parameters for progression rates, efﬁ cacy, and side effects were derived from 
the literature. Biochemical and histological progression to RT plus patient choice were 
modeled. Hormonal treatment was included as salvage therapy. Age-related mortality 
rates were applied throughout the model. For focal therapy, all low-risk patients 
received treatment. Failure of treatment led to patients commencing AS, while bio-
chemical progression at any time led to RT. Costs were taken from the UK NHS 
perspective. RESULTS: Over 25 years, AS delivered 13.3 QALYs (3.5% discount rate 
applied). The QALY value was heavily weighted by the utility of 0.84 associated with 
AS. Focal therapy delivered improved QALYs (14.6) over the same period and could 
be delivered for cost parity with AS. Cost-effectiveness is discussed. CONCLUSIONS: 
UK guidelines recommend AS for low-risk prostate cancer but do not meet the needs 
of patients, evinced by low QoL and by many patients choosing RT. Hence, AS has 
“hidden costs” in the UK system and there is a place for alternative treatment 
approaches such as focal therapies.
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OBJECTIVES: To assess cancer-related costs and related predictors among elderly 
breast cancer patients in the United States. METHODS: A retrospective study was 
conducted in subjects aged ≥65 years and diagnosed with breast cancer between 
January 1, 2000 and December 31, 2005. Patients were identiﬁ ed from the SEER-
Medicare linked database that combines clinical information on cancer cases with 
longitudinal (1991–2006) Medicare claims. An index date was deﬁ ned as the date of 
the ﬁ rst observed breast cancer diagnosis. Costs (2009 US$) were aggregated from 
subjects’ index date until death, Medicare disenrollment, or database end (December 
31, 2006) and included breast cancer-related surgery, radiotherapy, chemotherapy, 
and other medical encounters carrying a breast cancer diagnosis. Generalized linear 
models with a log link function and gamma distribution were used to assess predictors 
of costs. Age, race, stage at diagnosis, hormone receptor status (ER/PR), nodal status, 
Charlson comorbidity score, and chemotherapy use were key explanatory variables. 
RESULTS: The majority of the 66,217 breast cancer subjects selected were aged 70 
to 79 years (47%), Caucasian (88%), and in localized stage (67%) at diagnosis. 
Median follow-up was 50 onths. Approximately 5% of cases were diagnosed in the 
metastatic stage with a median follow-up of 26 months. Approximately 73% of 
subjects with metastatic disease died during follow-up compared to 21% of localized 
cases. Cancer-related adjusted costs per patient were $55,120 (median $25,991) for 
all cases and $153,421, $82,789, and $38,099, for metastatic, regional, and local stage 
cases, respectively. Regional and metastatic stage at diagnosis, increased age, increased 
number of cancer-positive lymph nodes, negative estrogen/progesterone receptor 
status, and chemotherapy use were found to be signiﬁ cant (P < 0.001) predictors of 
higher costs. CONCLUSIONS: Clinical characteristics indicating poorer prognosis are 
associated with signiﬁ cantly higher breast cancer costs. Patients with metastatic disease 
carry the highest cost of care despite having shorter follow-up and poorer survival.
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OBJECTIVES: Hepatocellular carcinoma (HCC) is a rapidly progressing, fatal disease. 
However, little is known regarding the hospitalization burden for these patients. This 
study compares the burden of hospitalizations due to HCC and hepatobiliary condi-
tions relative to other nonhepatobiliary comorbid conditions. METHODS: Insurance 
claims (Janaury 1, 2000—December 31, 2008) from a geographically diverse, com-
mercially insured US population were used to identify a cohort of patients with > = 1 
HCC claim (index = 1st claim), age > = 18, and no other cancer diagnoses in the year 
prior to index. Hospitalizations were grouped by primary diagnosis (ICD-9) codes 
into the following categories: 1) HCC and hepatobiliary, and 2) nonhepatobiliary. 
Hospitalization burden was compared between these categories based on: number of 
hospitalizations, time to occurrence since HCC diagnosis, length of stay, and cost 
(2009 USD). The number of hospitalizations was compared using a sign test for 
patient-level differences. The remaining parameters were compared using general 
estimating equations to adjust for patients with multiple hospitalizations. RESULTS: 
This study identiﬁ ed 2927 HCC patients (mean age 50.4 years, 57% male) and 2192 
hospitalizations. The subset of patients with > = 1 hospitalization (n = 1083, 37%) 
had an average of 2.02 admissions per patient with a median of 11.8 follow-up 
months. Compared to the nonhepatobiliary hospitalizations, the HCC and hepatobili-
ary hospitalizations had: a higher number of admissions (0.40 vs. 0.35 per patient; P 
< 0.001), a shorter time to occurrence (112 vs. 330 days; P < 0.001), a longer length 
of stay (6.4 vs. 5.4 days; P < 0.007), and a higher average cost per admission ($48,539 
vs. 23,221; P < 0.001). The total cost of HCC and hepatobiliary hospitalizations was 
2.3 times higher than nonhepatobiliary hospitalizations ($56,451,173 vs. $23,894,444). 
CONCLUSIONS: HCC and hepatobiliary conditions accounted for the majority of 
the hospitalization burden in liver cancer patients. Future HCC therapies demonstrat-
ing reduced symptom progression may reduce the prevalence, duration, and cost of 
HCC and hepatobiliary-related hospitalizations.
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OBJECTIVES: Human papillomavirus (HPV) infection is a necessary cause of cervical 
cancer and is associated with a subset of other anogenital (anal, vulvar, vaginal, penile) 
and head/neck cancers (oral cavity, oropharynx/pharynx, larynx). The overall HPV-
related disease burden is considerable in Europe. This study aimed to assess the 
hospital costs of HPV-related cancers for both genders in France. METHODS: Hos-
pitalization costs were collected from a recent publication for cervical cancer and from 
the French national hospital database (PMSI) for other cancers. Costs included hos-
pital stays, radiotherapy, and chemotherapy sessions. Annual costs for each cancer 
were estimated from the health-care payers’ perspective. RESULTS: In 2006, the 
annual costs of cervical cancer were estimated at c43.9 million. In addition, vulvar 
and vaginal cancers were associated with c9.7 million annually. For anal cancer, the 
annual costs were c20.3 million (male: c6.3 million; female: c14 million). Penile cancer 
hospitalizations represented c2.6 million annually. The estimated annual costs for 
head/neck cancers in 2007 for males and females, respectively, were c54.4 and c17.1 
million for oral cavity, c128.2 and c21.7 million for oropharynx/pharynx, and c47.8 
and c5.5 million for larynx. Considering the assumed proportion of cancers attribut-
able to HPV (cervical: 100%; vulvar: 34.7%; vaginal 76.8%; anal: 84.2%; penile: 
46.7%; oral cavity: 16.0%; oropharynx: 28.2%; larynx: 21.3%, in Europe), the 
overall hospitalization costs due to HPV-related cancers were estimated at c61.6 
million in males and c70.8 million in females. CONCLUSIONS: The hospital burden 
of HPV-associated cancers in males is almost similar as in females, in France. This 
burden is probably underestimated since outpatient and indirect costs were not 
included.
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OBJECTIVES: In our study, we estimated social and economic burden of hepatocel-
lular carcinoma (HCC) in Russian Federation resulting from HCC from the position 
of public health-care system. METHODS: All types of costs were calculated—direct 
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and indirect (the “cost of illness” analysis), connected with patient treatment at dif-
ferent stage of disease treatment. Epidemiology of ÍÑÑ in Russia was investigated: 
prevalence, incidence, structure of disease depending on age, disease progression, and 
death rate indicators. The expert opinion of real practice of HCC treatment was col-
lected. All these methods allowed to estimate the direct and indirect costs of HCC. 
RESULTS: HCC incidence rate was 2.4 patients per 100,000 population (85% in the 
structure of primary liver cancer). HCC incidence rate index was 8658 patients as of 
2008. In the HCC, structure intermediate stage prevails—61%, the terminal and local 
stages—30% and 9% correspondingly. HCC treatment costs were 2370 bln RUB 
(c67.7 mln) (2008). Direct medical costs were 2208 bln RUB (c63.1 mln) including 
inpatient care (90%), outpatient care (6.6%), and diagnostics (3.4%). Indirect costs 
were 0.161 bln RUB (c4.6 mln) including GDP loses (26%) and payment related with 
temporary disability (74%) The current HCC treatment standards do not correspond 
to international approaches. Very few patients with primary liver cancer get target 
pharmacotherapy. The analysis of actual practice of managing patients with HCC 
shows prevalence of drugs with no indications for usage from the point of view of the 
existing standards and recommendations (form 33% according to regional reimburse-
ment to 58% according to Federal reimbursement). CONCLUSIONS: Developing of 
new standards of HCC treatment including target therapy can reduce the cost of illness 
by reducing off-label use and optimizing the treatment strategy.
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OBJECTIVES: With 30,651 new cases diagnosed in 2005, lung cancer is the fourth 
most frequent cancer in France and the ﬁ rst in terms of mortality, with 26,624 deaths 
per year. The survival rate at 5 years is less than 15%. The purpose of this study was 
to describe the 2 years hospital undertaking of patients with a resection of lung tumor 
and to estimate associated hospital costs. METHODS: The 2006 to 2008 PMSI French 
hospital databases were used. Patients with a resection linked to a lung cancer (ICD10 
diagnoses: C33* and C34*) in 2006 were identiﬁ ed and followed up during 2 years. 
Hospital stays, chemotherapy, and radiotherapy sessions were extracted and associ-
ated costs (excluding expensive drugs) were assessed using DRG. Kaplan Meier 
method was applied to estimate associated costs over time, by taking into account 
survival probabilities. RESULTS: In 2006, 8798 patients were hospitalized for a resec-
tion of lung tumor of which 75.8% were men. Mean age at inclusion was 62.4 years; 
2343 patients (26.6%) died in hospital during follow-up. The mean number of hos-
pitalizations for repeated surgery was 0.11 per patient, 2.00 for radiotherapy sessions, 
2.99 for chemotherapy sessions, and 2.57 for other hospitalizations. Total mean 
hospital cost per patient was estimated at c16,169.89 for the 2 years follow-up. First 
surgery account for 48%, repeated surgeries for 6%, radiotherapy session for 2%, 
chemotherapy sessions for 8%, and other hospitalizations for 37%. First month of 
ﬁ rst year supported half of the total cost, and ﬁ rst year bore 86% of it. CONCLU-
SIONS: In France, lung resections for cancer represent a heavy charge for hospitals. 
During the follow-up period, major burden is dedicated to hospital stays especially 
for the ﬁ rst months. These results could be relevant to estimate the impact of coming 
drugs which will be associated to resection of lung tumor.
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OBJECTIVES: Estimating the amount and the structure of annual expenses for treat-
ment of breast cancer (BC) at different stages in Russia. METHODS: Indentifying the 
annual direct costs of treatment BC based on the Russian standard of treatment 
conﬁ rmed by Minister of Health of Russian Federation. Direct costs of BC include 
cost of medical services (MS) (hospitalizations, physician services, diagnosis, surgery, 
and other supporting services), and cost of pharmacotherapy (PT) (cytostatics, hor-
mones and antihormones, accompanying drugs, and other drugs). RESULTS: Annual 
direct costs of treatment BC totaled 138,680, 1,379,980, and 1,923,050 roubles at 
stages I–II, III, IV accordingly. With increase in weight of disease, the relative share 
of expenses for MS decreases and for PT increases. Analyzing the structure of costs 
at different stages showed that the cost of PT is substantial, especially at metastatic 
stage. The presence and relative share of components vary at different stages in struc-
ture of expenses for MS, in which expenses for radiotherapy share about 60% and 
68% at stage III and IV, accordingly. In structure of expenses for PT, the expenses 
for cytostatics are substantial and take 85% at both stages III and IV. Analyzing the 
gain of expenses for separate groups of drugs from stage III to IV showed that expenses 
for cytostatics and accompanying drugs have grown by 43% and 128% accordingly, 
while expenses for other groups have almost not changed. CONCLUSIONS: Expenses 
for treatment BC at different stages vary in size and structure, and rises with increase 
in weight of disease. With the amount of 51,865 patients with BC in 2007 (62.3%, 
26.3%, 10.5% at stages I–II, III, IV accordingly), we received total expenses for treat-
ment of 33,777.217.655 roubles ($1.125.907.255), in which expenses for treatment 
of stage I–II, III, IV are 4.481.031.599 roubles ($149,367,120), 18,823,610,290 
roubles ($627,453,676), and 10,472,593,166 roubles ($349,860,459), accordingly.
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OBJECTIVES: To carry out clinico-economic analysis of treatment of children with 
rhabdomyosarcomas on protocols CWS in Chelyabinsk Region, to estimate medical, 
social, and economic efﬁ ciency of technology. METHODS: We reviewed 21 patients 
<16 years old with rhabdomyosarcomas. All patients received therapy on protocols 
CWS. We used following methods of clinico-economic analysis: cost of illness, cost-
effectiveness analysis, and analysis of the kept years of a life. RESULTS: The sum of 
direct medical expenses for one patient has made US$16,904 dollars, and the total 
sum of direct medical expenses for treatment of 21 patients included in research, has 
made US$354,984. The overall survival rate was 52% that testiﬁ es to high medical 
efﬁ ciency of applied technology. For all groups of patients, the treatment keeps 694.4 
years of a life that makes 33 years of a life on one patient.The parity of a cost/efﬁ ciency 
for one patient has made US$512 dollars for 1 year of the kept life. Considering that 
in 2008 gross national product has made US$9.5 thousand per capita, an expense for 
1 year of the kept life in 18.5 times there is less than parameter of gross national 
product, means that expenses are justiﬁ ed. Before achievement of a pension age, the 
survived patients will work 422 years and will make gross national product for the 
sum US$4009 thousand. The survived patients provide the state with the income 11.2 
times the society for their treatment. CONCLUSIONS: The clinico-economic analysis 
has shown high medical, economic, and social efﬁ ciency of technology of treatment 
of children with rhabdomyosarcomas on protocols CWS.
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OBJECTIVES: To conduct a robust economic evaluation, it is necessary to describe 
current practice and associated costs. Available data on clinical pathways and cost of 
chemotherapy are clinical trial-based, which may not reﬂ ect UK National Health 
Service (NHS) practice. Practice-relevant costs of drug administration, patient moni-
toring and management of adverse events, required for a practice-relevant economic 
model, are not available. This study aimed to inform an economic evaluation by 
describing patient-based cost of NHS patients with advanced colorectal cancer (CRC) 
undergoing irinotecan-based chemotherapy. METHODS: Resource use data were 
collected from the medical records of 48 patients prescribed irinotecan-based (IrMdG) 
chemotherapy at a UK tertiary care center. Using the hospital perspective, data were 
collected from starting chemotherapy until treatment ended. Unit costs were assigned, 
based primarily on NHS Reference Costs 2008/09. Data were analyzed using descrip-
tive statistics and variations around the costs were obtained. Predictors of cost were 
identiﬁ ed from a stepwise multiple regression analysis (ordinary least squares). 
RESULTS: Total cost for 48 patients was £598,765.54 (UK £ 2008/09). Mean cost 
per patient was £12,474.28 (95% CI: £11,233.24–£13,715.32, median £13,307.82, 
range £3,024.48–£21,276.18). Cost components comprised: chemotherapy drugs 
(36.9%), chemotherapy delivery (21.4%), pharmacy cost (15.0%), oncology appoint-
ments (9.5%), central line insertion (5.0%), management of complications and comor-
bidities (5.1%), management of adverse events (4.9%), and imaging (2.2%). Signiﬁ cant 
predictors of increased cost (P < 0.05) identiﬁ ed from the stepwise regression were: 
number of chemotherapy cycles received (adjusted R2 0.81), neutropaenia (adjusted 
R2 0.83), no prior chemotherapy (adjusted R2 0.85), and full-dose chemotherapy 
(adjusted R2 0.86). CONCLUSIONS: This study provides the ﬁ rst data describing 
patient-based costs associated with current NHS practice in this patient group, derived 
from a pragmatic observational study with no trial protocol dictating practice. These 
data should be used in ensuing economic evaluations to ensure relevance to current 
clinical practice.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst, second, third, 
and fourth line of treatment in patients with metastatic colorectal cancer. Costs of 
chemotherapy regimens used as well as supportive care and medical procedures in 
Bulgaria will be estimated (as part of a multinational central European study). 
METHODS: This opinion-based study collected required data by online question-
naire. All information concerning treatment of colorectal cancer was based on experts 
opinion from four oncology centers in Bulgaria. Oncologists had access to medical 
records of approximately 1220 patients treated in year 2008. RESULTS: The leading 
ﬁ rst line regimen (60% of patients) was FOLFOX 4 (oxaliplatin, calcium folinate, and 
ﬂ uorouracil). The most commonly prescribed second-line regimen (50%) was 
FOLFIRI (irinotecan, calcium folinate, and ﬂ uorouracil). Capecitabine was the most 
popular in both the third- (26%) and fourth-line (4%) settings. The percentage of 
patients receiving supportive care increased with disease stage, from 1% in the ﬁ rst, 
